NO20056021L - Anvendelse av CS-866 til fremstilling av et medikament - Google Patents

Anvendelse av CS-866 til fremstilling av et medikament

Info

Publication number
NO20056021L
NO20056021L NO20056021A NO20056021A NO20056021L NO 20056021 L NO20056021 L NO 20056021L NO 20056021 A NO20056021 A NO 20056021A NO 20056021 A NO20056021 A NO 20056021A NO 20056021 L NO20056021 L NO 20056021L
Authority
NO
Norway
Prior art keywords
medicament
manufacture
arteriosclerosis
prophylaxis
treatment
Prior art date
Application number
NO20056021A
Other languages
English (en)
Other versions
NO334217B1 (no
Inventor
Toshihiko Fujiwara
Toshio Sada
Yoshio Tsujita
Naoyuki Maeda
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20056021L publication Critical patent/NO20056021L/no
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of NO334217B1 publication Critical patent/NO334217B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Anvendelse av CS-866 til fremstilling av et medikament for anvendelse ved profylakse eller behandling av arteriosklerose.
NO20056021A 1996-07-15 2005-12-16 Anvendelse av CS-866 til fremstilling av et medikament for anvendelse ved profylakse eller behandling av arteriosklerose. NO334217B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP18436896 1996-07-15
PCT/JP1997/002407 WO1998002183A1 (en) 1996-07-15 1997-07-11 Medicinal compositions

Publications (2)

Publication Number Publication Date
NO20056021L true NO20056021L (no) 1999-03-15
NO334217B1 NO334217B1 (no) 2014-01-13

Family

ID=16152008

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19990166A NO322314B1 (no) 1996-07-15 1999-01-14 Farmasoytisk preparat, sett som omfatter flere beholdere, samt anvendelse av troglitazon, pioglitazon og/eller BRL-49653 ved fremstilling av et medikament.
NO20056021A NO334217B1 (no) 1996-07-15 2005-12-16 Anvendelse av CS-866 til fremstilling av et medikament for anvendelse ved profylakse eller behandling av arteriosklerose.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO19990166A NO322314B1 (no) 1996-07-15 1999-01-14 Farmasoytisk preparat, sett som omfatter flere beholdere, samt anvendelse av troglitazon, pioglitazon og/eller BRL-49653 ved fremstilling av et medikament.

Country Status (19)

Country Link
US (1) US6610682B2 (no)
EP (2) EP0930076B1 (no)
KR (1) KR100540618B1 (no)
CN (2) CN1221259C (no)
AT (2) ATE283704T1 (no)
AU (1) AU714618B2 (no)
CA (1) CA2261040C (no)
CZ (2) CZ300089B6 (no)
DE (2) DE69734405T2 (no)
DK (2) DK0930076T3 (no)
ES (2) ES2250283T3 (no)
HK (1) HK1020260A1 (no)
HU (2) HU225415B1 (no)
IL (2) IL128059A (no)
NO (2) NO322314B1 (no)
NZ (1) NZ333723A (no)
PT (1) PT930076E (no)
RU (2) RU2183128C2 (no)
WO (1) WO1998002183A1 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047509A2 (en) * 1999-12-24 2001-07-05 Smithkline Beecham P.L.C. Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
EP1326604A2 (en) * 2000-04-12 2003-07-16 Novartis AG Combination of at least two compounds selected from an at1-receptorantagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
WO2003013609A1 (en) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Sustained-release medicines
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
RS20050590A (en) * 2003-01-31 2007-09-21 Sankyo Company Limited, Medicine for prevention of and treatment for arteriosclerosis and hypertension
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
JP4880591B2 (ja) 2004-06-04 2012-02-22 テバ ファーマシューティカル インダストリーズ リミティド イルベサルタンを含む医薬組成物
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
RU2441653C2 (ru) * 2005-05-31 2012-02-10 Милан Лэборетериз, Инк. Композиции, содержащие небиволол
ES2404939T3 (es) * 2005-06-27 2013-05-29 Daiichi Sankyo Company, Limited Preparación farmacéutica que contiene un antagonista del receptor de la angiotensina II y un bloqueador de los canales de calcio
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
JP5416408B2 (ja) 2005-10-04 2014-02-12 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ５−クロロ−ｎ−（｛（５ｓ）−２−オキソ−３−［４−（３−オキソ−４−モルホリニル）−フェニル］−１，３−オキサゾリジン−５−イル｝−メチル）−２−チオフェンカルボキサミドの新規多形および無定形
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
US20090076104A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched losartan
AU2009316899B2 (en) * 2008-11-19 2015-08-20 Boehringer Ingelheim Animal Health USA Inc. Compositions comprising 1-arylpyrazole alone or in combination with formamidine for the treatment of parasitic infection
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CN107648611A (zh) * 2017-09-18 2018-02-02 浙江大学 复方血管紧张素转换酶类抗瘢痕外用制剂
CN107617107A (zh) * 2017-09-18 2018-01-23 浙江大学 一种复方血管紧张素转换酶类抗瘢痕制剂
CN110075304B (zh) * 2019-05-29 2020-02-11 四川大学华西医院 一种治疗骨关节炎的药物组合物及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231080A (en) 1985-10-15 1993-07-27 Hoechst Aktiengesellschaft Method for the treatment of atherosclerosis, thrombosis, and peripheral vessel disease
DE3536687A1 (de) * 1985-10-15 1987-04-16 Hoechst Ag Verfahren zur behandlung von atherosklerose, thrombose und der peripheren gefaesskrankheit
US5223522A (en) * 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1989008651A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
CA2016467A1 (en) * 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
DE3925759A1 (de) * 1989-08-03 1991-02-07 Thera Patent Verwaltungs Gmbh Verwendung von ace-inhibitoren fuer die atheroskleroseprophylaxe
US5061694A (en) * 1989-10-23 1991-10-29 E. R. Squibb & Sons, Inc. Method for stabilizing or causing regression of atherosclerosis in coronary arteries employing an ace inhibitor
CA2026686A1 (en) 1989-10-30 1991-05-01 Werner Tschollar Method for preventing onset of type ii diabetes employing an ace inhibitor
GB2241890A (en) 1990-03-12 1991-09-18 Squibb & Sons Inc Preventing onset of or treating protein catabolism using an ace inhibitor
US5298497A (en) 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
US5616599A (en) 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
CA2229000C (en) * 1991-02-21 2002-04-09 Sankyo Company, Limited 1-biphenylimidazole derivatives, their preparation and their therapeutic use
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
CA2118706A1 (en) * 1992-07-13 1994-01-20 Saizo Shibata Novel thiazolidinedione compounds and use thereof
JPH0741423A (ja) 1993-02-24 1995-02-10 Sankyo Co Ltd 動脈硬化症治療剤
WO1994019347A1 (en) * 1993-02-24 1994-09-01 Sankyo Company, Limited Arteriosclerosis remedy
TW363959B (en) * 1994-03-23 1999-07-11 Sankyo Co Thiazolidine and oxazolidine derivatives, their preparation and their medical use
WO1995026188A1 (en) * 1994-03-29 1995-10-05 Merck & Co., Inc. Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
CA2650637A1 (en) 1996-04-05 1997-10-16 Takeda Pharmaceutical Company Limited Pharmaceutical composition containing angiotensin ii antagonist

Also Published As

Publication number Publication date
US6610682B2 (en) 2003-08-26
EP1175902B1 (en) 2005-10-19
HU0600501D0 (en) 2006-08-28
RU2220723C2 (ru) 2004-01-10
EP0930076B1 (en) 2004-12-01
PT930076E (pt) 2005-01-31
KR100540618B1 (ko) 2006-01-12
CN1221259C (zh) 2005-10-05
DE69731840D1 (de) 2005-01-05
DK1175902T3 (da) 2005-12-19
IL128059A0 (en) 1999-11-30
EP0930076A1 (en) 1999-07-21
ES2232873T3 (es) 2005-06-01
HUP0600501A3 (en) 2008-10-28
AU3459597A (en) 1998-02-09
CZ300089B6 (cs) 2009-01-28
KR20000023757A (ko) 2000-04-25
WO1998002183A1 (en) 1998-01-22
NO322314B1 (no) 2006-09-11
NO990166L (no) 1999-03-15
US20020013308A1 (en) 2002-01-31
CN1476833A (zh) 2004-02-25
CZ10299A3 (cs) 1999-06-16
CZ299162B6 (cs) 2008-05-07
AU714618B2 (en) 2000-01-06
ES2250283T3 (es) 2006-04-16
IL128059A (en) 2003-12-10
HU225415B1 (en) 2006-11-28
ATE306921T1 (de) 2005-11-15
DE69731840T2 (de) 2005-08-04
NO990166D0 (no) 1999-01-14
DE69734405D1 (de) 2006-03-02
HUP9903166A2 (hu) 2000-09-28
RU2183128C2 (ru) 2002-06-10
HU227399B1 (en) 2011-05-30
CA2261040A1 (en) 1998-01-22
CN1155409C (zh) 2004-06-30
EP1175902A1 (en) 2002-01-30
NZ333723A (en) 2000-09-29
DE69734405T2 (de) 2006-08-03
IL145758A (en) 2006-06-11
EP0930076A4 (en) 2001-10-04
HUP9903166A3 (en) 2003-09-29
HK1020260A1 (en) 2000-04-07
DK0930076T3 (da) 2005-01-31
CA2261040C (en) 2009-01-20
NO334217B1 (no) 2014-01-13
CN1230122A (zh) 1999-09-29
ATE283704T1 (de) 2004-12-15

Similar Documents

Publication Publication Date Title
NO20056021L (no) Anvendelse av CS-866 til fremstilling av et medikament
MX9700538A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
ZA961150B (en) Substituted isoxazoles for the treatment of inflammation.
NO893769L (no) Fremgangsmaate for behandling av naturgass.
DE3586959T2 (de) Desinfektionsverfahren sowie zusammensetzung dafuer.
DE69708149T2 (de) Doppelkammerbehälter sowie einzelne kammer dafür
EP0626174A3 (en) Method and composition for the prophylaxis and / or treatment of underactive organs.
FI931234A0 (fi) Foerfarande foer oevervakning av en patients tillstaond
DE58902899D1 (de) 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.
ATE228760T1 (de) Thrombininhibitoren
NO911459D0 (no) Anvendelse av metallion-komplekser som belegginhibitorer.
NO894129L (no) Fremgangsmaate for fremstilling av polysakkarider ved gjaering.
NO990450L (no) Behandling av sinnslidelser
AU7854094A (en) Use of amiodarone for the treatment of heart failure
ZA969586B (en) The use of cholinesterase inhibitors in the treatment of xerostomia
NO962503D0 (no) Anvendelse av penoksyfyllin ved behandling av multippel sklerose
DE69634044D1 (de) Menschliches cyclin i und das dafuer kodierende gen
SE8900564D0 (sv) Novel medicinal use
NO981320L (no) Oral anvendelse av (+)-O-demetyltramadol som smertemiddel
KR970060695U (ko) 구급약품상자
DE9404677U1 (de) Oberflächenbehandlungseinrichtung
SE8704471L (sv) Solarium
RU1809521C (ru) Генератор плазмы
DE29621211U1 (de) Therapietisch für Rollstühle u.dgl.
HK1040189B (zh) 在製造一8種用於治療動脈硬化的藥物中應用cs-866 (olmesartan)

Legal Events

Date Code Title Description
MK1K Patent expired